{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:58:34Z","timestamp":1776891514548,"version":"3.51.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer treatment-related erectile dysfunction and stress urinary incontinence are commonly treated with inflatable penile prosthesis (IPP) or artificial urinary sphincter (AUS). Given the association with androgens and penile\/urethral health, we aim to evaluate whether patients on androgen deprivation therapy (ADT) undergoing IPP or AUS surgery are at increased risk for reintervention, complication, or infection. We queried the TriNetX database for adult males receiving IPP or AUS. The ADT cohort included those on ADT 3 months before or any time after surgery. We performed sub-analysis for leuprolide and bicalutamide. Cohorts and outcomes were defined by Current Procedural Terminology and International Classification of Diseases codes. Propensity score matching was performed using age, prostate cancer, history of prostatectomy, and history of radiation. Outcomes were reintervention (revision, removal, or replacement), infection, and complication. Analytics were performed in March 2024. 13,432 patients received an IPP and 5676 received an AUS, 465 and 745 of whom were on ADT, respectively. The only significant AUS analysis was for patients on abiraterone having fewer reinterventions (10.5% vs 20.8%, RR\u2009=\u20090.50 [0.29, 0.88]). Patients receiving an IPP with ADT had fewer reinterventions (7.2% vs 12%, RR\u2009=\u20090.60 [0.39, 0.92]) and complications (12.7% vs 18.5%, RR\u2009=\u20090.68 [0.49, 0.95]). Those on a GnRH agonist had fewer reinterventions (7.4% vs 11.7%, RR\u2009=\u20090.63 [0.41, 0.98]) for IPP. Patients receiving an IPP on bicalutamide had fewer reinterventions (\u2009&lt;5.2%* vs 10.8%, RR\u2009=\u20090.48 [0.23, 0.99]) and on leuprolide had fewer complications (12.2% vs 19.3%, RR\u2009=\u20090.63 [0.43, 0.91]). The remainder of analyses showed no significant differences. Patients with IPP or AUS do not fare worse on ADT. Further evaluation into the duration of ADT may provide clinical context, but based on these results, ADT should not limit implant surgery.<\/jats:p>","DOI":"10.1038\/s41443-025-01015-8","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T13:19:31Z","timestamp":1738156771000},"page":"896-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Androgen deprivation therapy does not increase rates for reintervention, complication, or infection in primary penile implant or artificial urinary sphincter surgery: a retrospective cohort study from the TriNetX network"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9494-9633","authenticated-orcid":false,"given":"Zachary J.","family":"Prebay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6752-5521","authenticated-orcid":false,"given":"Aaron R.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-1400","authenticated-orcid":false,"given":"Paul H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"1015_CR1","first-page":"17","volume":"27","author":"V Shabataev","year":"2020","unstructured":"Shabataev V, Saadat SH, Elterman DS. Management of erectile dysfunction and LUTS\/incontinence: the two most common, long-term side effects of prostate cancer treatment. Can J Urol. 2020;27:17\u201324.","journal-title":"Can J Urol"},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41443-020-00386-4","volume":"33","author":"AB Nols\u00f8e","year":"2021","unstructured":"Nols\u00f8e AB, Jensen CFS, \u00d8stergren PB, Fode M. Neglected side effects to curative prostate cancer treatments. Int J Impot Res. 2021;33:428\u201338. https:\/\/doi.org\/10.1038\/s41443-020-00386-4","journal-title":"Int J Impot Res"},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer [published correction appears in N Engl J Med. 2023 Jun 8;388(23):2208]. N Engl J Med. 2016;375:1425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1606221","journal-title":"N Engl J Med."},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209:1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452","journal-title":"J Urol"},{"key":"1015_CR5","first-page":"216","volume":"27","author":"DE Magee","year":"2020","unstructured":"Magee DE, Singal RK. Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Can J Urol. 2020;27:216\u201322.","journal-title":"Can J Urol"},{"key":"1015_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/SPC.0000000000000624","volume":"16","author":"ML Lafontaine","year":"2022","unstructured":"Lafontaine ML, Kokorovic A. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer. Curr Opin Support Palliat Care. 2022;16:216\u201322. https:\/\/doi.org\/10.1097\/SPC.0000000000000624","journal-title":"Curr Opin Support Palliat Care"},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1152\/jappl.1999.87.6.2016","volume":"87","author":"J Antonio","year":"1999","unstructured":"Antonio J, Wilson JD, George FW. Effects of castration and androgen treatment on androgen-receptor levels in rat skeletal muscles. J Appl Physiol. 1999;87:2016\u20139. https:\/\/doi.org\/10.1152\/jappl.1999.87.6.2016","journal-title":"J Appl Physiol"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.21037\/tau.2018.02.05","volume":"7","author":"MD Hofer","year":"2018","unstructured":"Hofer MD, Morey AF. Role of androgens for urethral homeostasis. Transl Androl Urol. 2018;7:521\u20135. https:\/\/doi.org\/10.21037\/tau.2018.02.05","journal-title":"Transl Androl Urol"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MED.0b013e3283394e20","volume":"17","author":"DP Sieveking","year":"2010","unstructured":"Sieveking DP, Chow RW, Ng MK. Androgens, angiogenesis and cardiovascular regeneration. Curr Opin Endocrinol Diabetes Obes. 2010;17:277\u201383. https:\/\/doi.org\/10.1097\/MED.0b013e3283394e20","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1015_CR10","doi-asserted-by":"publisher","unstructured":"Prebay ZJ, Fu DH, Chung PH. Androgens and urethral health: how hypogonadism affects postoperative outcomes of patients undergoing artificial urinary sphincter or inflatable penile prosthesis placement. Urology. Published online November 2023. https:\/\/doi.org\/10.1016\/j.urology.2023.10.027","DOI":"10.1016\/j.urology.2023.10.027"},{"key":"1015_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11934-008-0083-3","volume":"9","author":"JJ Mulcahy","year":"2008","unstructured":"Mulcahy JJ. Penile implant infections: prevention and treatment. Curr Urol Rep. 2008;9:487\u201391. https:\/\/doi.org\/10.1007\/s11934-008-0083-3","journal-title":"Curr Urol Rep"},{"key":"1015_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0094-0143(05)70223-8","volume":"26","author":"CC Carson","year":"1999","unstructured":"Carson CC. Management of prosthesis infections in urologic surgery. Urol Clin North Am. 1999;26:829\u201339. https:\/\/doi.org\/10.1016\/S0094-0143(05)70223-8","journal-title":"Urol Clin North Am"},{"key":"1015_CR13","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJMra035415","volume":"350","author":"RO Darouiche","year":"2004","unstructured":"Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422\u20139. https:\/\/doi.org\/10.1056\/NEJMra035415","journal-title":"N Engl J Med"},{"key":"1015_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"key":"1015_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2265.2011.04189.x","volume":"76","author":"KB Rubinow","year":"2012","unstructured":"Rubinow KB, Snyder CN, Amory JK, Hoofnagle AN, Page ST. Acute testosterone deprivation reduces insulin sensitivity in men. Clin Endocrinol (Oxf). 2012;76:281\u20138. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04189.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1015_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.urology.2022.06.023","volume":"169","author":"RA Mann","year":"2022","unstructured":"Mann RA, Kasabwala K, Buckley JC, Smith TG, Westney OL, Amend GM, et al. The \u201cFragile\u201d urethra as a predictor of early artificial urinary sphincter erosion. Urology. 2022;169:233\u20136. https:\/\/doi.org\/10.1016\/j.urology.2022.06.023","journal-title":"Urology"},{"key":"1015_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.21037\/tau.2016.06.07","volume":"5","author":"GC Bailey","year":"2016","unstructured":"Bailey GC, Linder BJ, Rivera ME, Ziegelmann MJ, Rangel LJ, Elliott DS. The impact of androgen deprivation on artificial urinary sphincter outcomes. Transl Androl Urol. 2016;5:756\u201361. https:\/\/doi.org\/10.21037\/tau.2016.06.07","journal-title":"Transl Androl Urol"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01015-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:02:56Z","timestamp":1763431376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1038\/s41443-025-01015-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5412532\/v1","asserted-by":"object"}]},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u201cThis retrospective study is exempt from informed consent. The data reviewed is a secondary analysis of existing data, does not involve intervention or interaction with human subjects, and is de-identified per the de-identification standard defined in Section \u00a7164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert refreshed on December 2020.\u201d Per TriNetX publication guidelines. (\n                      \n                      , accessed January 12, 2025).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"PHC consults for and receives research support from Boston Scientific and Coloplast.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}